SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
| Autor: | Sumati Gupta, Srabani Bhaumik, Yolanda D. Mahnke, Kavita M. Dhodapkar, Ruslan D. Novosiadly, Cristina Maccalli, Yoshinobu Koguchi, Amanda W. Lund, Jean-Charles Grivel, Holden T. Maecker, Brent A. Hanks, Sylvia Janetzki, Siwen Hu-Lieskovan, Senthamil R. Selvan, Thomas O. Kleen, Tasha N. Sims, Yingdong Zhao |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_treatment Immunology immunomodulation Bioinformatics 03 medical and health sciences computational biology 0302 clinical medicine Resource (project management) Immune system Cancer immunotherapy biomarkers tumor antigens Neoplasms Position Article and Guidelines medicine Humans Immunology and Allergy Biomarker discovery RC254-282 Pharmacology business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cancer Immunotherapy medicine.disease Vaccination 030104 developmental biology Oncology 030220 oncology & carcinogenesis Molecular Medicine Biomarker (medicine) immunotherapy business |
| Zdroj: | Journal for Immunotherapy of Cancer Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020) |
| ISSN: | 2051-1426 |
| DOI: | 10.1136/jitc-2020-000705 |
| Popis: | Since the publication of the Society for Immunotherapy of Cancer’s (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and approval of immune checkpoint inhibitors, engineered cellular therapies, and tumor vaccines to unleash antitumor immune activity. The most notable feature of these breakthroughs is the achievement of durable clinical responses in some patients, enabling long-term survival. These durable responses have been noted in tumor types that were not previously considered immunotherapy-sensitive, suggesting that all patients with cancer may have the potential to benefit from immunotherapy. However, a persistent challenge in the field is the fact that only a minority of patients respond to immunotherapy, especially those therapies that rely on endogenous immune activation such as checkpoint inhibitors and vaccination due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers for each immunotherapy strategy, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement of immunotherapy. In this document, we summarize and update established biomarkers, guidelines, and regulatory considerations for clinical immune biomarker development, discuss well-known and novel technologies for biomarker discovery and validation, and provide tools and resources that can be used by the biomarker research community to facilitate the continued development of immuno-oncology and aid in the goal of durable responses in all patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|